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Abstract 
Introduction Five (5) hydroxitryptamine (5-HT) selective receptor 
agonists (triptans) were reported to have gastric motor effects. However, less 
is known about their role on gallbladder (GB) motility. 
Aim: Assessment of GB motility in patients treated with orodispersable 
triptans for migraine’s attacks. 
Patients and Methods: Out of 112 patients with various forms of migraine 
who required triptans while having headache attacks, followed-up in our 
ambulatory service, we have selected 30 patients diagnosed with mild to 
moderate migraine. These patients include: 15 with aura (3 men, 12 women, 
mean age=41,8±16,42 years) and 15 without aura (2 men, 13 women, mean 
age=47,73±18,50 years). Consequently, they had an ejection fraction (EF) of 
GB which is less than 60% (previously measured in intercritic period by 
elipsoid ultrasound Dodds method). Furthermore, no record of prokinetic or 
proton pump inhibitor treatments, gastric surgery, gallstones, collagen or 
thyroid disease, diabetes mellitus, cardiac, liver, kidney failure or cancer 
disease was recorded. The measurements of the GB were made while having 
a migraine attack, before and in every 15 minutes till 90 minutes. This was 
after receiving  5 mg  of orodispersable zolmitriptan. 
Results: There are no statistical significant difference between initially EF of 
the two groups (p=0,8190). Patients with migraine with aura showed a mean 
EF=42,53±4,31% before therapy. After therapy, the mean EF improved 
significantly: 48,80±3,23% (p=0,0001). Patients having migraine without 
aura displayed an initially mean EF=42,53±3,27%. In addition, they had a 
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very statistically significant response to therapy with important improvement 
of EF to 61,47±7,07% (p<0,0001). 
Conclusions: 5HT selective receptor agonists increased GB motility, in 
migraine attacks with a response above the cut-off range of EF, in patients 
having migraine without aura. 
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Introduction 
 Gastrointestinal (GI) motility is a complex process which includes 
different entities like: myoelectrical and contractile activity, compliance, 
tone, and movements known as gut transit. This complicated physiology of 
gut motility is under the supervision of local and circulating neurohumoral 
substances. However, one of them is hydroxitryptamine or serotonin (5-HT), 
which is an important neurohormonal transmitter. 5-HT is synthesized and 
stored mainly in two cell types: 90% in enterochromaphine (EC) cells and 
10% in the neurons of the gut. Then, it is released into the blood in various 
situations like: postprandially, in case of local changes of the pressure across 
the gut wall, or as a response to specific stimuli (Bearcroft et al., 1998). 
 Therefore, it is believed that 5-HT is released into the gut wall from 
the store zones located at the basolateral aspects of EC cells and then spread 
into the lumen (Hansen, 1997).  
 A lot of investigations have been done in order to reveal the exact 
role of 5-HT in the regulation of gut motility. The difficulty of this attempt 
was consistently increased by the existence of many 5-HT receptor subtypes 
with various locations and effects. Hence, that is why the precise roles of 5-
HT and 5-HT receptors are completely understood (Sarna et al., 2000).  
 It is now accepted  that 5-HT selective receptor agonists (triptans) 
represents one of the most important  modern therapy in migraine attacks, 
but  some of their pathophysiology and clinical implications are still subject 
to discussions (Bigal et al., 2009). 
 5-HT selective receptor agonists were reported to have esophageal 
effects at the level of the lower sphincter and gastric motor effects. Thus, this 
is mainly during the process of accommodation. Moreover, less is known 
about their role on gallbladder (GB) motility (Houghton et al., 1992; Cipolla 
et al., 2001; Moroa, 2004; Deixler & Helmke, 2005). 
 
Aim 
  The aim of this study is to assess GB motility response to 
orodispersable triptans in patients with migraine with or without aura, and 
previously known with impairment of the GB emptying. 
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Patients and Methods 
 In this study, 30 patients were diagnosed with migraine according to 
International Headache Society criteria (Olesen & Lipton, 1994). 15 with 
aura (3 men, 12 women, mean age=41,8±16,42 years) and 15 without aura (2 
men, 13 women, mean age=47,73±18,50 years) were  enrolled in this study. 
However, this was done after a thorough clinical examination and history 
taking. Biochemical blood tests such as blood smear, erytrocyte 
sedimentation rate (ESR), C reactive proteine (CRP), fasting sugar, alanin-
transaminases (ALT), blood nitrogen urea and creatinin, sodium and 
potasium, level of thyroid stimulating hormone (TSH), urine biochemical 
and bacteriological tests, electrocardiogram (ECG), thoracic X ray, and 
cerebral CT scans were performed in order to rule out any possible  
associated conditions. 
 The severity of migraine attacks was set according to Migraine 
Disability Assessment (MIDAS) questionnaire (Stewart et al., 2001). 
Headache pain intensity was assessed by a 10 point pain scale (0 indicating 
no headache and 10 indicating severe headache). The MIDAS questionnaire 
was used to assess disability related to headache during daily activities 
(work, home and family commitments, leisure or social activities). The 
migraine disability was graded into four classes according to MIDAS scores: 
0-5 as minimal, 8-10 as mild, 11-20 as moderate, and 21 or more as severe 
disability. 
 Measurements of GB motility were made using a cholecystokinetic 
meal consisting of 2 egg yolks (one egg yolk having about 55 calories, 4.5 
grams of total fat and 1.6 grams of saturated fat, 210 mg of cholesterol, 8 mg 
of sodium, and 2.7 grams of protein) in 112 migraineurs and 15  healthy 
controls. From these patients, we have selected 30 patients having a 
decreasing of the GB emptying under the cut-off value of 60% of EF. 
 Biliary sonograms were obtained with a very high resolution 
ultrasound machine General Electric Logiq 7, with a multifrequency convex 
array probe (3,5-5,5 MHz). Measurements included transverse and 
longitudinal views of the GB, with clear anatomical relationship to the liver, 
kidney, and portal vein, for a positive identification. With the patient in the 
supine position, the probe was placed at the right upper quadrant. Once GB 
was identified, longitudinal oblique and transverse axial views were 
obtained. In addition, we measured the 3 dimensions of GB (depth, height, 
width). For volume (V), calculations was done using the ellipsoid formula: 
Volume (V) = π/6 × (width × height × depth) (Dodds et al., 1985). The 
mathematical formula is given as: EF = (initial volume-maximum residual 
volume/initial volume) × 100. 
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 GB normal emptying ultrasound aspects in healthy controls, with 
normal EF above 60%, are depicted in figure 1. 
 Figure 1. Ultrasound aspects of GB motility in healthy controls 
 Ultrasound features of GB motility in patients, within intercritic 
periods with low EF, are illustrated in the figure below (Figure 2). 
Figure 2. GB motility in patients within intercritic periods 
 
 The same measurements of GB were made while having a migraine 
attack. This was done before and at every 15 minutes till it gets to 90 minutes 
after receiving  5 mg  of orodispersable zolmitriptan, with consecutive 
calculation of the EF.  
 Inclusion criteria include migraine with or without aura, intensity 
mild to moderate, treatment with 5-HT, and an ejection fraction (EF) of GB 
< 60%, which was previously measured using elipsoid ultrasound Dodds 
method.  
 Exclusion criteria include prokinetic or proton pump inhibitor 
treatments, previous gastric surgery with vagotomy, EF above 60%, 
gallstones, collagen or thyroid disease, diabetes mellitus, cardiac, liver or 
kidney failure, and cancer disease. 
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 Furthermore, the study was approved by the local ethical committee. 
Also, both the patients and their families provided written informed consent. 
  Statistical analysis was made using GraphPad software with the 
panel for continuous data. This was done with the calculation of the mean 
values and standard deviation, unpaired t test, and p values with CI= 95%. 
 
Results 
 As seen in the table below (table 1), there are no statistical significant 
differences between the two groups (migraine with aura versus migraine 
without aura) from a biochemical point of view. This was except for the 
body mass index (BMI) and sistolic blood pressure (BP), where p<0,0001. 
Table 1. Clinical and biochemical baseline data 
Parameters Group 1 Group 2      P 
Age (years) 41,8±16,42 47,73±18,50 0,36 (ns) 
BMI (kg/m²) 31,93±2,49 26,46±1,75 <0,0001 
Sistolic BP (mm Hg) 150,47±4,09 129,93±4,98 <0,0001 
Hemoglobin (g%) 12,96±0,69 13,087±0,57 0,59 (ns) 
Leukocytes (x10³/ml) 7,6±0,03 7,56±0,79 0,89 (ns) 
Platelets (x10³/ml) 267,67±60,26 268,33±55,41 0,97 (ns) 
ESR (mm/h) 12,57±2,74 13,73±3,73 0,35 (ns) 
CRP (IU) 0,7±0,26 0,97±0,24 0,66 (ns) 
ALT (IU) 28,53±4,72 29,93±6,81 0,53 (ns) 
Fast blood sugar (mg%) 96,47±4,72 86,40±6,17 0,97 (ns) 
TSH (IU) 4,03±0,78 4,00±0,66 0,92 (ns) 
Nitrogen urea (mg%) 38,8±7,91 35,87±7,70 0,31 (ns) 
Creatinin (mg%) 1,09±0,21 1,15±0,23 0,47 (ns) 
Sodium (mval/ml) 141,87±4,76 140,07±4,18 0,28 (ns)  
Potassium (mval/ml) 4,07±0,25 4,06±0,27 0,94 (ns) 
Legend: ns= nonsignificant 
 
 Subsequently, the first group of patients, having migraine with aura, 
tends to display more elevated values of BMI and sistolic BP. 
 Some ultrasound features of the motility of GB, in a patient after 
receiving zolmitriptan, are illustrated in the figure below (Figure 3): 
Figure 3. Maximal GB contraction after receiving zolmitriptan 
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 There was no statistical significant difference between initially EF of 
the two groups (p=0,8190). As seen in figure 4, patients with migraine with 
aura (group 1) showed a mean EF=42,53±4,31% before therapy. After 
therapy, the mean EF improved significantly:  48,80±3,23% (p=0,0001).  
Figure 4. Motility of GB with EF in group 1 (with aura) 
 
 Patients with migraine without aura (group 2), displayed an initially 
mean EF=42,53±3,27%. Hence, they had a very statistically significant 
response to therapy with the increasing of EF up to 61,47±7,07% 
(p<0,0001, above the cut-off value of 60%). 
Figure 5. GB motility with EF in group 2 (without aura) 
 
Discussions 
 Serotonin is a monoaminergic neurotransmitter with activities that 
modulate diverse central and peripheral functions. The central nervous 
system stores close to 2% of the body’s serotonin. At this level, serotonin 
affects food intake, sleep, anxiety, sexual behavior, and mood. On the other 
hand, in the peripheral system where close to 98% of the body’s serotonin is 
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synthesized and stored, serotonin operates as a peripheral hormone. This 
peripheral hormone affects vasoconstriction, intestinal motility, primary 
hemostasis, liver repair, and the control of the T cell-mediated immune 
system (Hansen, 2003).  
 A lot of study has been done with 5-HT 1, 2, 3,4, and 7 subtypes, in 
order to understand their role in the gut motility. Thus, it is now believed that 
subtype 1 of 5-HT stimulates the tone or motility of the lower esophageal 
sphincter and small intestine. It has an inhibitory effect over the tone or 
motility of the stomach, large intestine, and rectum. However, it seems that 
at some point, the multitude of 5-HT receptors, acting at the same level, may 
have similar or opposite actions e.g. either contraction or relaxation 
(Houghton et al., 1992; Borman and Burleigh, 1997; Coulie et al., 1999; 
Tack and Vanden Berghe, 2000). 
 The existence of a large variety of 5-HT receptors, makes the 
understanding of their various effects in different situations to be very 
difficult (Hixson, Lehrmann & Maickel, 1977). 
 In a mice model, in a Japanese study, the authors were able to 
demonstrate that injection with serotonin could result in a GB contraction, 
with the emptying of GB and the excretion of the bile (Hitoshi et al., 2010). 
 However, the working relation between exogenous administration of 
serotonin and production of cholecystokinin (CCK) at duodenal level is not 
clear. This is known a long time ago  as a major key in the excretion of bile 
by the GB contraction (Ivy & Oldberg, 1928). 
 Based on this view, an interesting observation states the fact that 
most 5-HT receptors do not seem to affect normal function, acting only in 
disease conditions. An example can be seen in a 5-HT receptor antagonist, 
and alosetron which delays intestinal transit in irritable bowel syndrome 
diarrhea-predominant (IBS-D) patients, but not in healthy controls (Camilleri 
et al., 1999; De Ponti and Tonini, 2001). 
 Some 5-HT 1B/D agonists like sumatriptan may also alter esophageal 
motility, favoring a gastro-oesofageal reflux (Houghton et al., 1994). 
Another study showed the effect of Sumatriptan on the gastric motility in 
humans pointing the fact that 5-HT1B/D receptor agonists delay the stomach 
emptying (Coulie et al., 1997). 
 Zolmitriptan is a 5-HT selective agonist of the 1B/1D subtype 
receptors. Thus, according to our results, it improves the gallbladder motility. 
This is achieved by the stimulation of the GB emptying in migraine attacks 
and in patients that previously had a decreasing of the EF of GB. 
 Consequently, this effect seems to be more prominent in patients 
having migraine without aura, by which the administration of zolmitriptan 
could normalize the EF, by increasing it above the range of 60%. 
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 By opposite, patients having migraine with aura, having also some 
minor associated metabolic issues like low grade obesity and higher blood 
pressure (nonmedicated), did not tend to have such a sustained response, 
resulting in an increasing of the EF but still below the cut-off range of 60%.  
 Whether or not zolmitriptan was orally administered in usual dosage, 
it should have an equal effect on GB contraction and emptying. This is 
irrespective of the severity or type of migraine that needs to be addressed in 
further discussions and investigations. 
 
Conclusion 
 5-HT selective 1B/1D receptor agonists, administrated as 
orodispersable zolmitriptan, increased previously disturbed GB motility in 
migraine’s attacks.  
 In patients with migraine without aura, we have observed a 
normalization of GB which empties with an increasing of EF in a range 
above the cut-off value of 60%. 
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